Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Grafts against cancer

05.02.2007
A major discovery to identify 'dangerous donors' in advance

A research team led by Prof. Claude Perreault, Université de Montréal, is announcing a major discovery in Genomics. This will generate a fundamental impact on the treatment of blood cancers (leukemias and lymphomes) by means of peripheral blood T-cell grafts.

Peripheral blood stem-cell grafts from immunologically-matched donors are still the best way to treat or cure patients with certain leukemias and lymphomas. In Canada alone, 10 000 people have benefited from this therapy. However, this type of graft is risky because of a major potential complication: "graft-versus-host disease" (GVHD). GVHD is a rejection of recipient tissues by the donor's T cells that see their new host as ‘non-self'. As many as 60% of recipients develop GVHD. In the best-case GVHD scenario, the disease markedly diminishes the patient's quality of life. In the most severe cases, GVHD may cause death. Because of the GVHD risk, graft of donor T cells can only be proposed to a small number of patients having leukemia or lymphoma. And until now, no reliable prediction could be made to determine if a recipient would be likely to incur GVHD or not. Published this week in the Public Library of Science Medicine (PLoS Medicine) this discovery provides a sure way of identifying cells that will cause GVHD.

Today's announced discovery opens the way to a reliable test to determine whether or not the cells of a donor will likely cause GVHD or not in the recipient, if the graft is performed. Creating a predictive test based on this discovery will have a considerable impact on the future of patients.

... more about:
»Cancer »GVHD »donor »leukemia

"A predictive test that will identify dangerous and non-dangerous donors will allow physicians to choose the best donor," explains Dr Perreault. "If no ‘non-dangerous donor' is found, then a physician can give the recipient a more intensive immuno-suppressive treatment to prevent GVHD. This opens the door to hematopoietic cell transplant personalized medicine."

"In this research, the special combinations of clinical design, advanced cell-sorting technology, large-scale gene expression profiling, and novel statistically-supported outcome-predictive computational analyses have produced together a very effective systems biology approach," says Biosystemix co-founder Dr. Larry Greller. "We are excited by the practicality and potential medical utility of these results, and look forward to their continuing validation in larger contexts," says Biosystemix co-founder Dr. Roland Somogyi.

For Génome Québec, it is a truly dramatic breakthrough that will not only improve and save lives, but also highlights the importance of backing and promoting knowledge in Genomics. According to Paul L'Archevêque, President and CEO of Génome Québec, "The researchers have done tremendous work! Clinical work will be transformed and moreover, first-line needs will be met in hospitals, from bench to bedside.".

The study involved 13 senior researchers and 50 patients suffering from haematological cancers and their respective immunologically-matched sibling donors. The patients were from the Maisonneuve-Rosemont hospital in Montreal. Statistical analysis and mathematical outcome-predictive modeling of these complex data were provided by the biotech company Biosystemix Ltd. In the coming months, the discovery will be extended in larger test phases to other hospitals in Canada and the US.

Damien Fiere | EurekAlert!
Further information:
http://www.iric.ca
http://www.genomequebec.com

Further reports about: Cancer GVHD donor leukemia

More articles from Life Sciences:

nachricht Closing the carbon loop
08.12.2016 | University of Pittsburgh

nachricht Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>